Fig. 6: Decreasing METTL14 expression leads to lower m6A modification and RNA degradation of ELMO1 in TNF-α-treated AS-MSC. | Nature Communications

Fig. 6: Decreasing METTL14 expression leads to lower m6A modification and RNA degradation of ELMO1 in TNF-α-treated AS-MSC.

From: TNF-α-mediated m6A modification of ELMO1 triggers directional migration of mesenchymal stem cell in ankylosing spondylitis

Fig. 6

a The m6A modification level of ELMO1 decreased after 100 ng/ml TNF-α treatment, and the m6A level of ELMO1 in AS-MSC (n = 9) was lower than that in HC-MSC (n = 9; P = 0.000003) with 100 ng/ml TNF-α treatment. b The degeneration curves of ELMO1 mRNA for HC-MSC and AS-MSC treated with 100 ng/ml TNF-α. c The t1/2 of ELMO1 mRNA in AS-MSC (n = 9) was higher than that in HC-MSC (n = 9; P = 0.01) after 100 ng/ml TNF-α treatment. d, e The METTL14 expression in AS-MSC (n = 9) treated with 100 ng/ml TNF-α was lower than that in HC-MSC (n = 9; P = 0.000024). f The mean fluorescence intensity of MET was higher in CD105+ MSC at the enthesis site in AS patients (n = 9) than those at the enthesis site in non-AS patients (n = 9; P = 0.000002). Scar bar = 20 μm. Data were analyzed using two-tailed Student’s t-test. Values are presented as the mean ± SD. ** Indicates P < 0.01, and *** indicates P < 0.001.

Back to article page